Phathom Pharmaceuticals Receives FDA Approval for VOQUEZNA for GERD Heartburn Relief in Adults

Jul 18, 2024, 12:04 PM

Phathom Pharmaceuticals has received FDA approval for its drug VOQUEZNA (vonoprazan) tablets. The medication is intended for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. This approval, announced on July 17 and July 18, marks a significant milestone for Phathom Pharmaceuticals, which has a short interest of over 40%. VOQUEZNA is a potassium-competitive acid blocker (PCAB), expanding its approval to cover more GERD patients.